Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CASC5
REST API REST API
Homo sapiens
CASC5 is differentially expressed in 248 experiments: 105 organism parts: lung, tonsil, ... (103 more);, 160 disease states: normal, healthy, ... (158 more);, 87 cell types 275 cell lines 26 compound treatments and 78 other conditions.
Synonyms hSpc105, CT29, KNL1, D40, hKNL-1, AF15Q14
Orthologs Casc5 (Mus musculus)   ENSGALG00000004616 (Gallus gallus)   ENSGALG00000004522 (Gallus gallus)   CASC5 (Danio rerio)   D3ZNX2_RAT (Rattus norvegicus)   Casc5 (Rattus norvegicus)   LOC100497601 (Xenopus laevis)   CASC5 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, cell division, M phase of mitotic cell cycle, protein binding, attachment of spindle microtubules to kinetochore, mitotic cell cycle, chromosome segregation, condensed chromosome kinetochore, acrosomal vesicle, mitotic prometaphase, nucleus, chromosome, nucleoplasm, nucleosome assembly, CenH3-containing nucleosome assembly at centromere, spindle assembly checkpoint, acrosome assembly
UniProt Accession Q8NG31, E9PPJ1, E7EUS1
Search EB-eye ENSG00000137812
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-GEOD-6573, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, E-GEOD-3202, ... (29 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-19639, E-GEOD-5823, E-GEOD-20081, E-GEOD-3529
A549
2
E-GEOD-6013, E-GEOD-3202
SW480
2
E-MEXP-1014, E-MTAB-37
SNU5
1
E-GEOD-15460
TERV
1
E-MTAB-62
NCIH2170
1
E-MTAB-37
269 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, ... (40 experiments)

Factor Value U/D Experiments
embryonic stem cell
2
E-GEOD-26672, E-MEXP-930
centroblast
2
E-GEOD-15271, E-TABM-702
mast cell
1
E-GEOD-3982
native fetal RPE
1
E-GEOD-18811
platelet
1
E-GEOD-2006
CD71+ early erythroid
1
E-AFMX-5
81 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-16363, E-MTAB-62, ... (54 experiments)

Factor Value U/D Experiments
myeloma
2
E-MTAB-62, E-MTAB-37
osteosarcoma
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
control
2
E-GEOD-21912, E-GEOD-16363
Nodular Goiter
1
E-MEXP-2442
154 more value(s).


Compound treatment

studied in E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-TABM-868, E-GEOD-5099, ... (16 experiments)

Factor Value U/D Experiments
cigarette smoke
1
E-TABM-127
unknown
1
E-GEOD-7307
Cxcl12
1
1
E-GEOD-7307
TNF
1
E-GEOD-15205
phorbol 12-myristate 13-acetate
1
E-GEOD-4600
rapamycin
1
E-GEOD-5824
20 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-21653

Factor Value U/D Experiments
62
2
1
E-GEOD-3494
78
2
1
E-GEOD-21653


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-GEOD-21138, E-GEOD-19665 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-4086

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-TABM-321, E-TABM-868, E-TABM-601, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-10315, E-TABM-440, E-GEOD-20505, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716, E-GEOD-2748 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-TABM-15, E-GEOD-16363, ... (26 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743, E-GEOD-5372

Karyotype
studied in E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-MEXP-1412, E-GEOD-1657, E-GEOD-1460, ... (8 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-22541, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-6532, E-GEOD-4922

Processing time: 0.344 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM